Introduction
Visfatin is an adipokine that is highly expressed in visceral fat and has various functions, including activation of insulin receptor and has insulin mimetic effects and improving insulin sensitivity. Laparoscopic sleeve gastrectomy (LSG) is a technically less complex surgical procedure which is promising for the weight loss and treatment of obesity and type 2 diabetes mellitus (T2DM).
Objectives
To evaluate serum levels of visfatin before and after sleeve gastrectomy surgery and their relationship with insulin resistance in obese diabetic and obese nondiabetic cases.
Patients and methods
This study was conducted on 80 patients with age ranged between 18 and 60 years who underwent LSG in our Bariatric Unit. They were divided into two groups: group 1consisted of 40 nondiabetic patients. Group 2consisted 40 patients who were diagnosed with T2DM of more than 1-year duration.
Results
When comparing groups, there is a highly statistical difference (≤0.001) as regards: fasting plasma glucose (FPG), homeostatic model assessment of insulin resistance (HOMA-IR), and glycated hemoglobin being higher in group 2. The visfatin level was significantly higher in group 2 (≤0.05).
Conclusion
Weight reduction after LSG is associated with a significant decrease in visfatin in both morbidly obese patients and patients with obesity and T2DM.